| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NVAX | Common Stock | Options Exercise | $883K | +32K | +134.01% | $27.60 | 55.9K | Oct 4, 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Options Exercise | $292K | +10.8K | +19.38% | $27.00 | 66.7K | Oct 4, 2021 | Direct | F1 |
| transaction | NVAX | Common Stock | Sale | -$232K | -1.39K | -2.09% | $166.98* | 65.3K | Oct 4, 2021 | Direct | F1, F2 |
| transaction | NVAX | Common Stock | Sale | -$646K | -3.75K | -5.74% | $172.36* | 61.6K | Oct 4, 2021 | Direct | F1, F3 |
| transaction | NVAX | Common Stock | Sale | -$874K | -5.04K | -8.18% | $173.45* | 56.5K | Oct 4, 2021 | Direct | F1, F4 |
| transaction | NVAX | Common Stock | Sale | -$541K | -3.1K | -5.48% | $174.56* | 53.4K | Oct 4, 2021 | Direct | F1, F5 |
| transaction | NVAX | Common Stock | Sale | -$632K | -3.6K | -6.74% | $175.61* | 49.8K | Oct 4, 2021 | Direct | F1, F6 |
| transaction | NVAX | Common Stock | Sale | -$829K | -4.7K | -9.43% | $176.48* | 45.1K | Oct 4, 2021 | Direct | F1, F7 |
| transaction | NVAX | Common Stock | Sale | -$1.58M | -8.89K | -19.7% | $177.58* | 36.2K | Oct 4, 2021 | Direct | F1, F8 |
| transaction | NVAX | Common Stock | Sale | -$1.53M | -8.56K | -23.63% | $178.46* | 27.7K | Oct 4, 2021 | Direct | F1, F9 |
| transaction | NVAX | Common Stock | Sale | -$592K | -3.3K | -11.92% | $179.48* | 24.4K | Oct 4, 2021 | Direct | F1, F10 |
| transaction | NVAX | Common Stock | Sale | -$90.3K | -500 | -2.05% | $180.58* | 23.9K | Oct 4, 2021 | Direct | F1, F11 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -32K | -46.72% | $0.00 | 36.5K | Oct 4, 2021 | Common Stock | 32K | $27.60 | Direct | F1, F12 |
| transaction | NVAX | Stock Option (Right to Buy) | Options Exercise | $0 | -10.8K | -100% | $0.00* | 0 | Oct 4, 2021 | Common Stock | 10.8K | $27.00 | Direct | F1, F13 |
| Id | Content |
|---|---|
| F1 | The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| F2 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.94 to $167.04, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F3 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.92 to $172.88, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F4 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.93 to $173.92, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F5 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.01 to $174.97, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F6 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.01 to $175.99, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F7 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.01 to $176.99, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F8 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.03 to $178.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F9 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.04 to $178.98, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F10 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.05 to $180.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F11 | The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.31 to $180.74, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
| F12 | Twenty-five percent (25%) of the shares subject to this option grant under the Company Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through each such vesting date. |
| F13 | Vesting of the shares subject to this option grant under the Plan were subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments on the first of each month over the following three (3) years subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested, if at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of the Company's common stock met or exceeded $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days. The Company's common stock did not meet $160.00 for twenty (20) consecutive trading days and therefore 9,171 shares were cancelled. |